Allogenetics
Hanover
About Allogenetics
Allogenetics GmbH provides a unique solution to the problem of organ rejection following transplantation. It is a distinct first-in-class therapy since it addresses the transplant rather than paralyzing the patient's immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.8M
- Funding stage: Seed
- Last round: Seed (Aug 2024)
- Website: allogenetics.de
- Phone: +49 511 563585-110
Industries & Categories
Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/allogenetics-50645 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.